LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on meningioma. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Meningioma.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Meningioma: Market overview
Meningioma is a tumor that arises from the meninges, membranes that surround the brain and spinal cord. Although it is not exactly a brain tumor, it is included in this category because it may compress or squeeze the adjacent brain tissue, nerves, and vessels. It is the most common type of tumor that forms in the head. Most meningiomas grow very slowly, often over many years, without causing symptoms. But in some cases, their effects on adjacent brain tissue, nerves or vessels may cause serious consequence. Since most of the meningiomas grow slowly, they do not always require immediate treatment and can be monitored over time.
According to a senior market research analyst at Technavio, “A surge in the incidence of the primary brain tumors in general and of meningiomas specifically has been registered in many countries during the past decades. It is said that the main reason for this surge could be the aging population, better access to advanced healthcare facilities, and diagnostic procedures, and the changes in coding classification for the meningiomas registered.”
Meningioma: Segmentation analysis
This pipeline analysis report segments the meningioma market based on RoA (oral, intravenous, and intramuscular), targets (PD-1, CDK4 and CDK6, mTORC1/mTORC2, MEK1/MEK2, RTK, NMDA receptor, PP2A, DNA, PDL1, and somatostatin receptor), geographical segmentation (the US, Austria, Spain, France, Italy, and Belgium) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
